Søgning


Flere søgeindstillinger

Søgning på udtrykket 'hiv' giver 81 resultater


Dokumenter [21] Sider [7] Kalender [4] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
Dokumenter [21]

Europæisk guideline om hvornår, der bør testes for HIV. Udgivet af "HIV in Europe", et paneuropæisk initiativ for tidligere diagnosticering og behandling af HIV. Kort version på dansk kan findes på www.eurotest.org/projects-collaborations/indicator-condition-guided-hiv-testinghides/guidance-hiv-indicator-conditions

Udarbejdet af arbejdsgruppe fra Dansk Selskab for Infektionsmedicin og Dansk Fertilitetsselskab.

Fællesregional retningslinje for udlevering af forebyggende medicin mod HIV (PrEP), udgivet af Danske Regioner.

Udarbejdet af arbejdsgruppe under Dansk Selskab for Infektionsmedicin

Udarbejdet af DSI's arbejdsgruppe vedrørende antiretroviral terapi

Om håndtering og opfølgning for at minimere risiko for smitte med bl.a. HIV, HBV og HCV.

…medicin i form af f.eks TNF-α hæmmere eller andre immunsupprimerende biologiske lægemidler, hvor der er øget risiko for tuberkulosereaktivering. Guideline dækker ikke børn, personer med medfødt immundefekt, HIV positive, patienter i dialyse, patienter med dysreguleret diabetes, silicose, erhvervede immundefekter eller patienter i konventionel kortvarig kemoterapi. Denne guideline omhandler ikke klassisk smitteopsporing blandt tuberkuloseeksponerede eller udredning på mistanke om aktiv tuberkulose.

…r (BMSL) til patienter i forhold til risiko for tuberkulose (TB), Humant Papillom Virus (HPV), Hepatitis B og C (HBV og HCV), Varicella Zoster Virus (VZV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) og Humant Immundefekt Virus (HIV) og øvrige infektioner. Vejledningen er udarbejdet af repræsentanter fra Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Reumatologisk Selskab (DRS), Dansk Dermatologisk Selskab (DDS) og Dansk Selskab for Infektionsmedicin (DSI).

Arrangeret af Yngre Infektionsmedicinere

Bl.a. om HIV, hepatitis, resistente bakterier og immundefekt

Bl.a. om HIV, hepatitis, influenza og CNS infektioner

Bl.a. om HIV, hepatitis, cystisk fibrose og nye guidelines

Correspondence regarding "Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy"

DANHIV blev oprettet som en regional klinisk kvalitetsdatabase i RegionH i sommeren 2015. Imidlertid har projektet fungeret som Det Danske HIV Kohorte Studie (DHK) siden 1998. DHK har fungeret som en kombineret kvalitetsdatabase og forskningsdatabase. Data i DHK går tilbage til 1. januar 1995, hvorfor vi allerede nu kan vise udviklingen over en lang årrække for de forskellige indikatorer.

Bl.a. om sygdom efter udlandsrejse, resistens og kroniske virale infektioner

Forfattet af DSI's arbejdsgruppe vedrørende antiviral behandling

Bilag til Retningslinjer for screening og profylakse før behandling med biologiske lægemidler (2023)

Sider [7]

…nter 1). Kort over Hvidovre Hospital: www.hvidovrehospital.dk/praktisk-information/transport/Documents/Kort%20over%20Hvidovre%20Hospital.pdf. Delkursusledere: Ole Søgård og Lene Ryom. Formål: At kursisten skal opnå en forståelse af HIV-infektionen, herunder viden om dens epidemiologi, patogenese, diagnose, forebyggelse, behandlingsmulighederne og prognose.

Formål: At kursisten skal opnå en forståelse af HIV-infektionen herunder viden om dens epidemiologi, patogenese, patofysiologi, diagnose, forebyggelse, behandlingsmuligheder og prognose samt viden om diagnostik og behandlingen af AIDS-definerende sygdomme og de hyppigste sexuelt overførte sygdomme. Tid og sted: Hvidovre Hospital. Lokale 10 i undervisningsbygningen. Delkursusledere: Ann-Brit Eg Hansen og Ole Kirk. Program: Mandag 3.

…me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet.

…na Weis, Britta Tarp, Lone Mygind National Strategi for Hepatitis C (Sundhedsstyrelsen 2023), Kronisk viral hepatitis: Nina Weis (tovholder), Peer Brehm Christensen, Alex Lund Laursen Hepatitis B (2018), Hepatitis C (2022), HIV: Antiretroviral terapi: Jan Gerstoft (tovholder), Jens Lundgren, Henrik Nielsen, Alex Laursen, Niels Obel, Isik Somuncu, Gitte Kronborg, Ann-Brit Eg Hansen Antiviral behandling af hiv smittede personer (2024), Fertilitetsbehandling ved HIV og.

…giske infektioner og kronisk hepatitis: Dato for næste kursus 2026: Sted. Odense Universitetshospital Delkursusledelse. Lone Mygind, Micha Jepsen og Belinda Mössner Tidligere kurser. 4. og 5. december 2023 3. og 4. december 2020 HIV-infektion: Næste kursus. 30. og 31. oktober 2025 (2 dage): Sted. Aarhus Universitetshospital (AUH)  Delkursusledelse. Ole Schmeltz Søgaard og Lene Ryom Nielsen  Program. Afventer Tidligere kurser. 12. og 13. oktober 2022 7.

…me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet.

…iklen summerer på en rimelig afbalanceret måde den globale kontrovers, som 2013 var præget af, om hvorvidt ART skal benyttes som forebyggende middel, som led i en individuel-baseret eller en folkesundsbaseret strategi for at reducere smittespredning af HIV.

Professor Henrik Nielsen kommenterer: Trods indiskutable fremskridt i den farmakologiske behandling af HIV/AIDS er der fortsat områder med plads til forbedring. Blandt patienter i kronisk behandling er HAND (HIV-associated neurocognitive disorder) et af disse eksempler.

Professor Jens Lundgren kommenterer: I 2014 var verden optaget af Ebola udbruddet i Vest Afrika – et udbrud der blev erkendt hurtigt (om end den internationale assistance lod vente på sig). Vedlagte artikel belyser detaljeret hvorledes HIV pandemien startede i 1920’erne og hvor det jo som bekendt tog over 60 år af finde ud at der overhovedet var et problem. Synes artiklen er godt skrevet og giver et indblik i Afrika for 90 års siden og de ingredienser der skulle til for at ud.

Professor Lars Østergaard kommenterer: Jeg vil gerne anbefale vedlagte artikel som julemånedslæsning. Grundene er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor.

Professor Jens Lundgren kommenterer: I 2015 nåede WHO sit mål om at få 15 million på behandling. START studiet afklarede også at alle HIV+ personer har gavn af at starte på HIV behandling. Der er fortsat mere end 20 millioner der endnu ikke er startet. Hovedparten bor i ressource svage lande hvor adgang til monitorering af HIV mængden er begrænset og behandlingsskift pga behandlingssvigt er derfor primært drevet af klinik og CD4 tals måling.

… dolutegravir, især når det kombineres med TAF fremfor tenofovir DF, forårsager markant vægtøgning. Især hos kvinder med mørk hudfarve. Artiklen gør indtryk af en række grunde:. Da dolutegravir blev markedsført havde det profilen som det eneste HIV præparat uden bivirkninger. Læring: der er ingen medicinske præparater der ikke har nogle bivirkninger, og typen af bivirkninger kan ikke altid forudsiges udfra markedsføringsstudier (fase I-III).

Professor Jens Lundgren kommenterer: Første lægemiddel mod SARS-CoV-2 udviklet fra ”bunden” – bruger et gammel trick fra HIV medicinen (ritonavir) for at holde plasma koncentrationerne oppe. Læringen er, at det tager tid at lave nye lægemidler helt fra bunden, men det er noget nær en verdensrekord så hurtigt som det skete under pandemien – både hvad angår vacciner (hvor det tog < 1 år fra design ex vivo til markedsføring), men altså ca 2 år for lægemidler som dette.

Professor Lars Østergaard kommenterer: Indimellem kommer der studier, som er så overbevisende, at det sætter en ny behandlingsstandard. Det kan f.eks.

Professor Troels Lillebæk kommenterer: Interessant systematisk review i AIDS om udbytte af screening for tuberkulose infektion (TBI) blandt personer, der lever med HIV (PLHIV) i tuberkulose lav-incidens lande (som Danmark) . Inddraget i alt 51 undersøgelser med 65.930 PLHIV hvoraf 12 % havde en positiv LTBI-test, som var stærkt relateret til oprindelsesland og eksponering for TB ).


Kalender [4]
30. oktober, Aarhus Universitetshospital (AUH)
13. juni, Panum instituttet, København
4. juni, Barcelona, Spanien
4. juni, Barcelona, Spanien
Nyt fra tidsskrifterne [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?

AIDS
12.05.2025
Objectives: . Assess the relationships of gut microbiota (GMB)-related metabolites in feces and blood with GMB and type 2 diabetes (T2D) in the context of HIV infection, the presence of which could disrupt host metabolism. Design: . We conducted a cross-sectional study among 111 women with HIV (WWH) and 56 women without HIV (WWOH) in the MACS/WIHS Combined Cohort Study. Methods: .
AIDS
12.05.2025
Introduction: . In 2023, 28.8 million (72%) of 39.9 million people living with HIV worldwide were on treatment with viral suppression, while 11.1 million (28%) people had viraemia with the risk of onward HIV transmission. That year, there were 1.3 million new HIV infections worldwide. To achieve elimination of HIV worldwide by 2030, we need a combination of intensive HIV testing and treatment, as well as pre-exposure prophylaxis (PrEP).
AIDS
12.05.2025
…jective: . This study aimed to evaluate the agreement between self-reported physical activity (PA) levels, as measured by the Lipid Research Clinics Physical Activity Questionnaire (LRCQ), and objective measures obtained through actigraphy in people with HIV . Methods: . Cross-sectional data were analyzed from the 130 people with HIV who completed the LRCQ and wore an actigraphy device for 7–10 days.
AIDS
12.05.2025
Background: . Cell metabolism is critical for adequate responses by immune cells. Although changes in immune cell populations in uninfected children born to women living with HIV (HEU children) are well described, little is known regarding the metabolic characteristics of their immune cells. Methods: .
AIDS
12.05.2025
Objective: . Sexually transmitted infections (STIs) are associated with an increased risk of HIV transmission, raising concerns in case of virus resistant (R) to the drugs currently approved for pre-exposure prophylaxis (PrEP). We explored the incidence of STIs in men who have sex with men with HIV (MSMWH) and resistance to tenofovir/emtricitabine (TXF/FTC) and/or cabotegravir (CAB). Design: .
PLoS One Infectious Diseases
10.05.2025
by The PLOS One Editors .
BMJ Open
10.05.2025
. Background. In high-income countries (HICs), migrants living with HIV (MLHIV) are more likely than other HIV subpopulations to encounter problems which hamper their adherence to the care process; these include social and administrative insecurity, discrimination and psychological distress. . Objective. This systematic review aimed to determine the specific features of adherence to the HIV care process among MLHIV in HIC. . Method.
BMJ Open
10.05.2025
…to the development of some components of metabolic syndrome (MetS), specifically glucose intolerance, weight gain and defective lipid metabolism. This study determined the relationship between dolutegravir (DTG) and MetS in a cohort of persons living with HIV (PWH) initiating DTG-based regimen in Ghana. . Design. A 2-year observational prospective study was conducted from September 2020 to August 2022. . Setting.
BMC Infectious Diseases
10.05.2025
. Background. HIV remains a critical global public health challenge, with 39 million people living with HIV as of 2022 and over 40.4 million lives lost to the epidemic. In China, the burden is similarly significant, with over 1.33 million HIV cases reported as of 2024. The challenges are particularly acute in western regions like Yunnan Province, which face resource limitations, socio-demographic disparities, and a high prevalence of HIV among ethnic minorities.
Science Advances
10.05.2025
Science Advances, Volume 11, Issue 19, May 2025.
Science Advances
10.05.2025
Science Advances, Volume 11, Issue 19, May 2025.
Tropical Medicine & International Health
9.05.2025
Tropical Medicine &International Health, EarlyView.
Clinical Infectious Diseases
9.05.2025
…sence of a positive Mycobacterium tuberculosis culture, and treatment completed or in care) at 18 months and time to sputum culture conversion (SCC).Results . In total, 248 participants were included, 173 (69.8%) of whom were human immunodeficiency virus (HIV) positive. Culture conversion by 90 days was 96.8% (median time to SCC: 29 days, 95% confidence interval [CI]: 27–31). Treatment success was 37.5% (93/248).
PLoS One Infectious Diseases
9.05.2025
by Gilbert Ndziessi, Sylvie Boyer, Charles Kouanfack, Julien Cohen, Fabienne Marcellin, Jean-Paul Moatti, Eric Delaporte, Bruno Spire, Christian Laurent, Maria Patrizia Carrieri, for the Stratall ANRS 12110/ESTHER Study Group .
PLoS One Infectious Diseases
9.05.2025
by Marie Suzan-Monti, Charles Kouanfack, Sylvie Boyer, Jérôme Blanche, Renée-Cécile Bonono, Eric Delaporte, Patrizia M. Carrieri, Jean-Paul Moatti, Christian Laurent, Bruno Spire, Stratall ANRS 12-110/ESTHER Study Group .
PLoS One Infectious Diseases
9.05.2025
by Gilbert Ndziessi, Julien Cohen, Charles Kouanfack, Fabienne Marcellin, Maria Patrizia Carierri, Gabrièle Laborde-Balen, Camélia Protopopescu, Avelin Fobang Aghokeng, Jean-Paul Moatti, Bruno Spire, Eric Delaporte, Christian Laurent, Sylvie Boyer, for the Stratall ANRS 12110/ ESTHER Study Group .
Trends in Microbiology
9.05.2025
Tuberculosis (TB) and HIV coinfection present a significant global health challenge worldwide. While most individuals infected with Mycobacterium tuberculosis (Mtb) have clinically asymptomatic latent TB infection (LTBI), those with immunosuppressive conditions, such as HIV, are at higher risk for reactivation and disseminated TB. HIV exacerbates TB progression by impairing immune responses, particularly through the depletion of Mtb-specific CD4+ T cells and chronic immune activation.
Lancet Microbe
8.05.2025
Nef-mediated MHC-I downregulation might contribute to HIV-1 persistence during long-term ART. Strategies to inhibit Nef-mediated MHC-I downregulation could represent a viable therapeutic avenue to reduce the size of the latent reservoir in vivo, improving treatment outcomes in people with HIV-1.
Journal of Infectious Diseases
8.05.2025
Abstract . Background . Islatravir, a nucleoside reverse transcriptase translocation inhibitor, exhibits high potency against HIV-1, with a long intracellular half-life. The safety, tolerability, and pharmacokinetics of once-monthly oral islatravir were evaluated in adults at low risk of acquiring HIV-1.Methods . In this double-blind placebo-controlled trial, participants were randomized 2:2:1 to receive 6 once-monthly doses of islatravir 60 mg, islatravir 120 mg, or placebo.
Aktuelle smitsomme sygdomme [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?

Eurosurveillance latest updates
9.05.2025
. Background. HIV testing based on indicator conditions is recommended to diagnose HIV earlier. . . Aim. Our aim was to assess opportunities for earlier diagnosis of HIV. . . Method. This is a retrospective study on people living with HIV (PLWH) included in the national HIV register.
Medscape Infectious Diseases
8.05.2025
A cross-sectional analysis shows that long-acting antiretroviral therapy sustains viral suppression regardless of initial viremia in patients with HIV. . Medscape Medical News
Morbidity and Mortality Weekly Report (MMWR)
7.05.2025
CDC updates HIV nonoccupational postexposure prophylaxis recommendations Meta Keywords:
Medscape Infectious Diseases
7.05.2025
AIDS-related illnesses continue to be the most common cause of hospital admissions for people living with HIV worldwide, followed by bacterial infections, a meta-analysis shows. . Medscape Medical News
Medscape Infectious Diseases
29.04.2025
Patients in historically redlined neighborhoods experience significantly longer delays in achieving HIV viral suppression than those in non-redlined areas. . Medscape Medical News
Medscape Infectious Diseases
16.04.2025
Despite being effective, PrEP uptake in Europe remains low due to issues like cost, access, and stigma, hindering its potential to reduce HIV transmission. . Medscape Medical News
ProMED
11.04.2025
. . . HIV/AIDS - INDIA (03): (UTTARAKHAND). ************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . [1] . Date: Wed 9 Apr 2025 . Source: The Times of India (TOI), Times News Network (TNN) [edited] . timesofindia.indiatimes.com/city/dehradun/23-haridwar-jail-inmates-hiv-positive-dm-seeks-report/articleshow/120136259.cms . . .
Medscape Infectious Diseases
11.04.2025
-The Trump administration plans to remove all the members of a presidential advisory council on HIV/AIDS and provided no timeline for replacing them as the government. . Reuters Health Information
Medscape Infectious Diseases
9.04.2025
Global progress against HIV is at risk as aid cuts could trigger millions of new infections and deaths, potentially setting efforts back to 2010 levels, experts warn. . Medscape Medical News
Medscape Infectious Diseases
9.04.2025
Patients who lose medication access will experience disease progression and risk for death, experts emphasize. . Medscape Medical News
ProMED
1.04.2025
. . . HIV/AIDS - INDIA (02): (TRIPURA, KERALA). ****************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . In this post: . [1] Tripura . [2] Kerala . . ****** . [1] Tripura . Date: Wed 26 Mar 2025 . Source: The Indian Express [edited] . indianexpress.com/article/india/tripura-hiv-adults-assembly-cm-manik-saha-9907180/ . . .
Medscape Infectious Diseases
1.04.2025
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally. . Reuters Health Information
Medscape Infectious Diseases
28.03.2025
Nucleoside reverse transcriptase inhibitor resistance does not affect efficacy when adults with HIV suppressed on bPI-based regimen switch to bictegravir plus emtricitabine plus tenofovir alafenamide. . Medscape Medical News
Medscape Infectious Diseases
25.03.2025
There could be 2,000 new HIV infections a day across the world and a ten-fold increase in related deaths if funding frozen by the United States is not restored or replaced,. . Reuters Health Information
Morbidity and Mortality Weekly Report (MMWR)
20.03.2025
This report describes adolescent girls and young women with functional disabilities had who higher prevalence of experiencing sexual, physical and emotional violence.
Medscape Infectious Diseases
20.03.2025
Doubling the dose of tuberculosis treatment did not drive up rates of depression and anxiety. . Medscape Medical News
Medscape Infectious Diseases
19.03.2025
Visuospatial scores improved significantly with semaglutide compared with placebo. . Medscape Medical News
Medscape Infectious Diseases
19.03.2025
The U.S. health department said on Tuesday it is reviewing the Centers for Disease Control and Prevention's HIV prevention division for overlap with other agencies but no. . Reuters Health Information
Medscape Infectious Diseases
18.03.2025
The Trump administration's decision to pause U.S. foreign aid has 'substantially disrupted' supply of HIV treatments in eight countries, which could soon run out of these. . Reuters Health Information
Medscape Infectious Diseases
17.03.2025
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with HIV without preliminary drug resistance testing in a phase 4 trial. . Medscape Medical News

DSI på

Følg os på linkedin.com/company/dansk-selskab-for-infektionsmedicin

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2025 Dansk Selskab for Infektionsmedicin

CVR: 33634307

infmed.dk
Version: 2.2.1
PHP version: 8.0.30
Design: Christian Philip Fischer
Side indlæst på 1.049 s

Cookies og privatliv